RANK ligand and osteoprotegerin in myeloma bone disease.
about
Management of endocrine disease: Secondary osteoporosis: pathophysiology and managementDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementReceptor activator of NF-κB ligand induces cell adhesion and integrin α2 expression via NF-κB in head and neck cancers.Computational modeling of interactions between multiple myeloma and the bone microenvironmentAdvances in the understanding of myeloma bone disease and tumour growth.The critical role of IL-34 in osteoclastogenesisThe best of both worlds - managing the cancer, saving the bone.Bone disease in multiple myeloma: pathophysiology and management.A review of osteocyte function and the emerging importance of sclerostinGenetic factors influencing the risk of multiple myeloma bone diseaseNew insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.Neoplastic development in plasma cells.Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.New insights into the pathophysiology and management of bone disease in multiple myeloma.Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1a) in human multiple myeloma.Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.Orofacial pain in cancer: part I--mechanisms.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.Treatment strategies for bone disease.Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.Dickkopf-1: a suitable target for the management of myeloma bone disease.Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications.The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma.New understanding and treatments for osteoporosis.Role of cancer stem cells in spine tumors: review of current literature.Skeletal and extraskeletal actions of denosumab.Proteasome inhibitors and bone disease.Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy.Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.Myeloma cells suppress osteoblasts through sclerostin secretion.The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell.
P2860
Q26998249-7C544356-6FB2-421E-AE3D-75C19673C00BQ27011865-623C9392-71E4-4915-8FA2-F524CEFBFBF6Q27326719-286DB0E9-9B16-4EEC-8684-4D9F7E7B19BFQ28477867-9648EB07-B40F-47E2-9B28-57B9EC00FF06Q33829022-8583206A-9DFF-4B7D-A79A-192CEEA7AE6AQ33873578-0BAAAA21-786D-4223-ACFD-1209CD6308DDQ33920055-A2CF7322-213B-4C36-B632-AC32EAFC69B6Q34045789-8D562759-A5E0-4FF3-8C86-3BC92D7E0714Q34264395-874C657B-0526-4C5F-81C2-B985D2E027F0Q34674841-9B046B6C-41E0-462C-9CA7-1AC52E63601EQ34773850-90FD3442-0D67-4275-869E-FF57A721A9B6Q35067806-4969E309-3CDE-4ECC-90B7-FF9A8F094F32Q35170940-0A476384-CCB9-44C4-8A7C-04FB6CF8B124Q35220234-DDD63A3D-7849-4A5E-A857-C19441AB2BA9Q35591086-8B4367DC-C81D-4C3D-9D2D-3DB2132F0692Q35678932-1069F652-F095-4C67-95E8-194799A98442Q35883830-CA62D50B-9A1A-4AF4-89FB-6307C398A8F5Q35959002-949A3D2D-10AD-4601-BD75-34C8DF439284Q36194693-0C71D850-3453-49EB-A715-5EF8F17D788FQ36742501-296D20BF-0045-43F2-A760-23AD746F6327Q36831523-0E04F4E9-AAC4-4844-92A2-D28A1F6C825AQ36860987-F6598405-C43D-45E7-BD5B-9E06734CBF32Q36870585-4AFA839E-EB3B-4522-A280-07812086F433Q36891815-6FAD0CF5-E946-451F-8088-E1F7BFC5C89CQ36902828-CE096DEB-B60F-4E43-8E80-531EC6D2FDEAQ37176560-B267ACF9-E502-448D-BC71-0B672E7D4DE0Q37493951-32F30775-808C-44EF-B826-3D510CE480D5Q37521086-02DE2405-4F1B-4D2C-912B-2F6B90A491C6Q37687419-0BB05D0B-4920-4E75-83A2-19A063CD6914Q37829690-48505065-3BEB-4900-B183-60139F53A7D0Q37865591-B93318EE-50A3-44AA-8B07-CA95DC32F4BEQ37969683-840AF902-AD0F-49E6-B273-338DC35A4A9FQ37993701-32D63808-613F-4D70-A1BA-BFD69B73D3BCQ38009712-D3F7374F-23B3-48D5-9885-7023CB23FBE1Q38021042-0C76CACC-0E19-426D-AC8F-88BA0C546BC0Q38153026-214813FB-56E4-4F15-BB55-D103F8893FE0Q38155200-334FC4B9-A804-4915-B111-9596B115F2DAQ38189791-7EE2C75D-ADE6-4077-BAB4-1A8494439BB7Q38323256-7F838591-0600-4B6E-8AAA-D2B41CC14DFDQ38569328-1C81DBBE-D71C-48A0-81FC-E6EDA84DB6E9
P2860
RANK ligand and osteoprotegerin in myeloma bone disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
RANK ligand and osteoprotegerin in myeloma bone disease.
@ast
RANK ligand and osteoprotegerin in myeloma bone disease.
@en
RANK ligand and osteoprotegerin in myeloma bone disease.
@nl
type
label
RANK ligand and osteoprotegerin in myeloma bone disease.
@ast
RANK ligand and osteoprotegerin in myeloma bone disease.
@en
RANK ligand and osteoprotegerin in myeloma bone disease.
@nl
prefLabel
RANK ligand and osteoprotegerin in myeloma bone disease.
@ast
RANK ligand and osteoprotegerin in myeloma bone disease.
@en
RANK ligand and osteoprotegerin in myeloma bone disease.
@nl
P2093
P1433
P1476
RANK ligand and osteoprotegerin in myeloma bone disease
@en
P2093
Christian Alexander Kühne
Ivana Zavrski
Orhan Sezer
Ulrike Heider
P304
P356
10.1182/BLOOD-2002-09-2684
P407
P577
2002-11-07T00:00:00Z